How it works
The CancerAid Plus program is an innovative educational program designed to help individuals gain better control of their cancer care. The program is based on evidence-based science to give patients the right tools to achieve better outcomes.
The CancerAid Plus Program includes:
An educational program with a series of informative articles based on clinically-proven science
Educational videos focused on improving patient understanding of cancer care
Motivational articles and advice written by other patients describing their experiences
Access to the award-winning CancerAid app, with the ability to track symptoms, medications & activity - 100% free to use and download.
Following the conclusion of the program, patients have ongoing access to all of the CancerAid content and in-app tools, and are encouraged to reach out to the CancerAid team if they have any further needs.
PBS Information: Zoladex 10.8mg. Restricted benefit for locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.
PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING. FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA.
Symptoms - Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197-8.
Exercise - Cormie P, Atkinson M, Bucci L, Cust A, Eakin E, Hayes S, et al. Clinical Oncology Society of Australia position statement on exercise in cancer care. The Medical journal of Australia. 2018;209(4):184-7.
Diet & Nutrition - Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA: A Cancer Journal for Clinicians. 2012;62(4):242-74.
Sleep - Otte JL, Carpenter JS, Manchanda S, Rand KL, Skaar TC, Weaver M, et al. Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained? Cancer medicine. 2015;4(2):183-200.